Acute Liver Failure, Hepatic Encephalopathy, Intracranial Hypertension
Conditions
Brief summary
The main objective of this study is to investigate the effect of Prometheus liver support dialysis on intracranial pressure, cerebral metabolism and circulation in patients with acute liver failure.
Detailed description
Acute liver failure (ALF) is a highly mortal medical condition often complicated by multiorgan failure. Apart from severe coagulopathy ALF is characterized by onset of hepatic encephalopathy and in many cases intracranial hypertension (ICH) with the risk of cerebral incarceration. The pathogenesis behind ICH is incompletely understood and the therapeutic options are limited. Prometheus (R) liver support dialysis offers a system that apart from regular high-flux hemodialysis to a certain extent is able of removing albumin-bound substances from the patient - a feature that theoretically could benefit patients with ALF. In this study we intend to investigate the effect of 6-8 hours of Prometheus (R) liver support dialysis on cerebral metabolism, ICH and cerebral bloodflow (CBF) in patients with ALF. The study is designed as a open, prospective and randomized study, where a control-group treated with 6-8 hours of continuously veno-venous hemodiafiltration (CVVHDF) and standard medical treatment (SMT) is compared to the intervention group treated with Prometheus (R) liver support dialysis and SMT. The study is designed as a cross-over study so that included patients will be treated in both groups in a randomized order. The primary end-points are treatment effect on intracranial pressure, CBF and cerebral oxidative metabolism (lactate/pyruvate-ratio). We use a intracranial monitoring system from Integra/Camino (R) (United States) in combination with CMA microdialysis system and bedside analyzer (CMA-600) (Stockholm, Sweden).
Interventions
DEVICEPrometheus (R) liver support dialysis
6-8 hours of dialysis
DEVICECVVHDF (Continuously Veno-Venous Hemodiafiltration)
6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
Sponsors
Rigshospitalet, Denmark
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* acute liver failure * and grade II-IV encephalopathy * and persistent raised arterial ammonia-concentration above 150 micromol/L * and informed consent from closest relative and general practitioner
Exclusion criteria
* withdrawal of informed consent * severe untreated infection * active bleeding within 48 hours * suspicion of malignant liver disease * severe heart insufficiency or middle artery pressure below 60 mmHg in spite of vasoactive therapy * pregnant or lactating women * disseminated intravascular coagulation * clinical suspicion of cerebral damage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| treatment effect on cerebral oxidative metabolism (lactate/pyruvate-ratio) | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| treatment effect on intracranial pressure | 24 hours |
Countries
Denmark
Outcome results
None listed